OncoMatch/Clinical Trials/NCT05636787
Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients
Is NCT05636787 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Treosulfan and Melphalan for multiple myeloma.
Treatment: Treosulfan · Melphalan — Clinical trial investigating the chemotherapeutic compound treosulfan (Trecondi® Ideogen) in myeloma patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: induction chemotherapy — first-line
myeloma patients after standard first-line induction treatment
Cannot have received: anti-cancer investigational agent
Use of any anti-cancer investigational agents within 14 days prior to the expected start of trial treatment
Lab requirements
Kidney function
creatinine clearance ≥35 ml/min
Cardiac function
lvef ≥40% within three months prior to start of study hdct
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify